Thr308
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > O-GlcNAc Site Page: > Thr308  -  Akt1 (human)

Site Information
kDGAtMKtFCGtPEy   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 40216800

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , modification-specific antibody ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
neuroblastoma ( 1 )
Relevant cell line - cell type - tissue:
SH-SY5Y (neural crest) ( 1 )

Upstream Regulation
Treatments:
IGF-1 ( 1 ) , PUGNAc ( 1 )

References 

1

Gandy JC, Rountree AE, Bijur GN (2006) Akt1 is dynamically modified with O-GlcNAc following treatments with PUGNAc and insulin-like growth factor-1. FEBS Lett 580, 3051-8
16684529   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.